[Clinical aspects of treatment with amiodarone]
- PMID:28643175
- DOI: 10.1007/s00399-017-0516-0
[Clinical aspects of treatment with amiodarone]
Abstract
Amiodarone has multiple and complex electrophysiological effects that render it a very effective antiarrhythmic drug for the treatment of both, supraventricular and ventricular arrhythmias. Proarrhythmic effects of amiodarone in patients with structural heart disease are rare. However, extracardiac adverse effects occurring in association with amiodarone treatment are frequent and feared. These adverse effects have usually been related to total amiodarone exposure (i. e., dose and duration of treatment). Parallel to a more frequent use of lower amiodarone maintenance doses (100-200 mg/day), the incidence of severe unwanted extracardiac side effects has decreased. High-dose maintenance regiments (daily dose ≥300 mg) are usually obsolete. This paper discusses recommendations regarding the monitoring of cardiac and extracardiac side effects of amiodarone. They need to be regarded by physicians using amiodarone to ensure long-term safety of amiodarone therapy.
Keywords: Amiodarone; Antiarrhythmic drugs; Drug-related side effects; Proarrhythmia; Sudden death.
Similar articles
- Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety.Lee KL, Tai YT.Lee KL, et al.Clin Cardiol. 1997 Apr;20(4):372-7. doi: 10.1002/clc.4960200414.Clin Cardiol. 1997.PMID:9098598Free PMC article.
- New antiarrhythmic drugs in pediatric use: amiodarone.Paul T, Guccione P.Paul T, et al.Pediatr Cardiol. 1994 May-Jun;15(3):132-8. doi: 10.1007/BF00796325.Pediatr Cardiol. 1994.PMID:8047495Review.
- [Amiodarone-induced thyroid gland dysfunctions].Gassanov N, Dietlein M, Caglayan E, Erdmann E, Er F.Gassanov N, et al.Dtsch Med Wochenschr. 2010 Apr;135(16):807-11. doi: 10.1055/s-0030-1251935. Epub 2010 Apr 13.Dtsch Med Wochenschr. 2010.PMID:20391312Review.German.
- Clinical efficacy and safety of intravenous Amiodarone in infants and children.Figa FH, Gow RM, Hamilton RM, Freedom RM.Figa FH, et al.Am J Cardiol. 1994 Sep 15;74(6):573-7. doi: 10.1016/0002-9149(94)90746-3.Am J Cardiol. 1994.PMID:8074040Clinical Trial.
- Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.Gill J, Heel RC, Fitton A.Gill J, et al.Drugs. 1992 Jan;43(1):69-110. doi: 10.2165/00003495-199243010-00007.Drugs. 1992.PMID:1372862Review.
Cited by
- [Second look: practical diagnostic and therapeutic checks in neurorehabilitation].Knecht S, Schmidt-Wilcke T.Knecht S, et al.Nervenarzt. 2020 Apr;91(4):324-336. doi: 10.1007/s00115-020-00887-z.Nervenarzt. 2020.PMID:32123934Review.German.
- [Antiarrhythmic drugs in the present day].Allgaier R, Duncker D.Allgaier R, et al.Inn Med (Heidelb). 2024 Aug;65(8):762-769. doi: 10.1007/s00108-024-01745-9. Epub 2024 Jul 15.Inn Med (Heidelb). 2024.PMID:39009875Review.German.
- Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal.Lonare S, Hazarika M, Das CK.Lonare S, et al.Indian J Pharmacol. 2020 Nov-Dec;52(6):533-534. doi: 10.4103/ijp.IJP_714_20.Indian J Pharmacol. 2020.PMID:33666199Free PMC article.No abstract available.
- Comparative study of the protective effects of coenzyme Q10 and cinnamon extract on possible kidney damage and dysfunction of amiodarone in rats.Ekici O, Gul A, Keskin E, Bulut S, Suleyman B, Mammadov R, Cicek B, Demir O, Gunay M, Suleyman H.Ekici O, et al.Clin Exp Nephrol. 2025 Apr;29(4):414-426. doi: 10.1007/s10157-024-02584-6. Epub 2024 Oct 30.Clin Exp Nephrol. 2025.PMID:39476229
- Amiodarone-Induced Lung Toxicity: A Case Initially Not Correctly Framed.Scaramozzino MU Sr, Sapone G, Plastina UR, Nucara M.Scaramozzino MU Sr, et al.Cureus. 2023 Mar 28;15(3):e36818. doi: 10.7759/cureus.36818. eCollection 2023 Mar.Cureus. 2023.PMID:37123694Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources